Deborah Slipetz ^Investor

Deborah Slipetz is a highly experienced drug discovery executive leader with expertise in respiratory and immunology. She has successfully led programs from target identification to clinical proof of concept, contributing to the development of Tredaptive and Singulair. With a background in in vitro and in vivo pharmacology across multiple therapeutic areas, Deborah has extensive executive management experience and a proven track record in project leadership. She holds a PhD in Pharmacology from McGill University and has a strong background in biology and molecular genetics. Deborah is a Six Sigma Green Belt and excels in drug development.